Abstract:To the Editor: Acinetobacter baumannii is a major cause of nosocomial infections associated with high morbidity and mortality, primarily in immunocompromised patients in Intensive Care Units. Multidrug-resistant (MDR) and extensively drug resistant (XDR) A. baumannii had become a serious widespread threat to nosocomial infections.[1] There are limited effective antimicrobial agents against these strains. Moreover, the mortality rate of A. baumannii infections was associated with inappropriate antimicrobial treatment.[12] It is critical to use effective antimicrobials for treating these A. baumannii infections. Meanwhile, discovering new antimicrobials and useful combinations of approved drugs against these strains is urgent. Thus, in this study, we discussed the in vitro activity of different antibacterial agents, including imipenem (IMI), meropenem (MEM), amikacin (AMK), ciprofloxacin (CIP), cefoperazone/sulbactam (CPS), and sulbactam (SUL) in combination with each other against MDR A. baumannii isolated from different provinces of China. Nonduplicate A. baumannii strains were collected from hospitals in different provinces of China. All strains had been identified using microbial identification system. Minimum inhibitory concentrations (MICs) had been determined by the agar dilution method as described by the Clinical and Laboratory Standards Institute protocol. We considered a strain as MDR if it was resistant to two or more antibiotic classes.[1] Moreover, we strictly selected 116 MDR A. baumannii strains, which were all resistant to MEM, IMI, AMK, and CIP based on the MICs surveillance results, to evaluate the in vitro activities of combinations agents using agar checkerboard dilution method.[3] The combination test involved six clinically, commonly used agents, including imipenem (Merck, USA), meropenem (DSM Pharm., Suzhou, China), amikacin (Xudong Haipu, Shanghai, China), ciprofloxacin (Shangyu Xinyao, Zhejiang, China), cefoperazone/sulbactam (Pfizer, USA), and sulbactam (NICPBP, Beijing, China). The dose of each agents ranges from 1/32 MIC to 4 MIC. Freshly prepared cation-supplemented Mueller-Hinton agar and Mueller-Hinton Broth (Oxoid, Thermo Fisher, British) were used for this study. Results were interpreted by the fractional inhibitory concentration index (FICI).[3] The FICI was calculated for each combination using the following formula: FICI = FICA + FICB, where FICA = MIC of drug A in combination/MIC of drug A alone, and FICB = MIC of drug B in combination/MIC of drug B alone. The FICI was interpreted as follows: synergy, FICI ≤0.5; indifference, 0.5 4.0. Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as internal quality control strains. The in vitro antibacterial activities of each combination are compared in Table 1. In the synergy studies, the combination of carbapenem (IMI or MEM) with amikacin (AMK) exhibited the best activity, which showed synergistic against about 50% of tested strains. And the following were SUL plus AMK and SUL plus carbapenem (IMI and MEM). The only antagonism effect happened in the combination between AMK and CIP. We found that antimicrobial agents in combination with AMK would have relative higher synergy response while the combination with CIP primarily produces indifferent response.Table 1: The percentage of the FICI of the six antimicrobial agents combination with each other against 116 MDR Acinetobacter baumanniiThe ideal therapy approach to microbial infections should be based on the evaluation of individual isolate susceptibility pattern. Considering carbapenem-resistant A. baumannii strains were usually resistant to all classes of antimicrobials other than tigecycline and colistin, the overall treatment strategy generally depended on the susceptibility of carbapenems. For those carbapenem-resistant A. baumannii, colistin, tigecycline, and rifampicin may be the alternatives; however, these agents were generally considered as the last choice for MDR A. baumannii and they also had obvious limits as described previous.[12] The combination of different antimicrobial agents was another strategy to overcome these MDR A. baumannii. On the one hand, combination of agents with different antimicrobial mechanisms may exert an enhanced pharmacodynamic effect, namely synergism. On the other hand, to a certain extent, combination treatment would prevent emergence of resistance.[4] Our study found that AMK in combination with carbapenems (IMI and MEM) would produce relative higher synergy response, the following combination were SUL plus AMK and SUL plus carbapenems. The previous survey had shown that combinations of IMI or MEM with SUL or ampicillin/sulbactam were potential choice for the treatment of carbapenem-resistant strains. At present, clinical data about combination therapy was relative less.[5] The ideal therapy approach to infections should be initially based on the evaluation of in vitro susceptibility surveillance. In this study, we provided valuable in vitro data for clinicians’ strategy against MDR A. baumannii infections through studying the synergy effect of six commonly used agents on large-scale samples, which partly represent the characteristics of China strains. Further studies to investigate in vivo effect for its clinical significance are needed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

Genetic Characterization of Multidrug-Resistant Acinetobacter baumannii and Synergy Assessment of Antimicrobial Combinations

Genes related to chloramphenicol,tetracycline,rifampicin and trimethoprim-sulfamethoxazole resistance in multi-drug resistant Acinetobacter baumannii

Sample cluster analysis of resistance genes in multidrug-resistant Acinetobacter baumannii

Detection of 22 beta-lactamase genes and enzyme activities in multi-drug resistant Acinetobacter baumannii

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

Exploring Synergistic Combinations in Extended and Pan-Drug Resistant (XDR and PDR) Whole Genome Sequenced Acinetobacter baumannii

Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Acinetobacter baumannii Patient Isolates

In Vitro Activity of Different Antibacterial Agents in Combination with Each Other Against Multidrug-resistant Acinetobacter Baumannii

Epidemiological Analysis of Multidrug-Resistant Acinetobacter baumannii Isolates in a Tertiary Hospital Over a 12-Year Period in China

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii

Activities of Colistin- and Minocycline-Based Combinations Against Extensive Drug Resistant Acinetobacter Baumannii Isolates from Intensive Care Unit Patients

Polymyxin B Heteroresistance and Adaptive Resistance in Multidrug- and Extremely Drug-Resistant Acinetobacter baumannii

Mechanistic insights into synergy between nalidixic acid and tetracycline against clinical isolates of Acinetobacter baumannii and Escherichia coli

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information.

Genetic Diversity of Antimicrobial Resistance and Key Virulence Features in Two Extensively Drug-Resistant Acinetobacter baumannii Isolates

Acinetobacter baumannii Antibiotic Resistance Mechanisms

1651. in Vitro Synergy Test and Clinical Outcome of Antibiotics Combination Regimens for Carbapenem-Resistant Acinetobacter Baumannii

Prevalence Of Genes Of Oxa-23 Carbapenemase And Adeabc Efflux Pump Associated With Multidrug Resistance Of Acinetobacter Baumannii Isolates In The Icu Of A Comprehensive Hospital Of Northwestern China

Multidrug Resistance of Acinetobacter baumanii and Homogeneous Analysis

Acinetobacter baumannii in suspected bacterial infections: Association between multidrug resistance, virulence genes, & biofilm production